WuXi Biologics (Cayman) Inc. (WUXI13)
Thailand Exchange · Thailand · prices in THB · close of 19 Oct 2026
Key indicators
| Last close | THB 3.080 |
|---|---|
| 52-week range | 1.800 – 3.640 |
| Return, 1 month / 3 months | −0.6% / +29.4% |
| Return, 1 year / 3 years | – / – |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 41 |
| Volatility (1 year) | 54.3% |
| Worst drawdown (1 year) | -26.8% |
| Average daily value traded | 0.01M THB |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
WuXi Biologics is a contract research, development and manufacturing organisation serving the biopharmaceutical industry. The company works with drug developers around the world on biologic medicines, offering services that span discovery, clinical development and commercial manufacturing of antibodies and related protein-based therapies. Its customers include pharmaceutical and biotechnology companies that rely on outside partners for process development and production capacity. WuXi Biologics is based in China and operates manufacturing and research facilities there and in other countries.
On this site WuXi Biologics (Cayman) Inc. appears as a stock on the Thailand Exchange (Thailand), code WUXI13, with prices in Thai baht (THB). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
WuXi Biologics (Cayman) Inc. (WUXI13) trades on the Thailand Exchange in Thailand. It last closed at THB 3.080 on 19 October 2026.
Its price-based Market X-Ray is 58 out of 100 (a fair price profile), ranking 528 of 1,348 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Thailand Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 26.3% | ||
| From 52-week high | -14.9% | ||
| Momentum | 92 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 29.4% | ||
| 6-month return | 40.0% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 54.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.8% | ||
| Liquidity | 0 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M THB | ||
| Zero-volume days | 31.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −10.5% |
|---|---|
| 1 month | −0.6% |
| 3 months | +29.4% |
| 6 months | +40.0% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 3.158 / 2.438 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.089 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Thailand Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.